{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
norethindrone acetate
to a specific field?
Status:
Investigational
Source:
NCT03201419: Phase 2 Interventional Completed Nocturia
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT00951743: Phase 2 Interventional Unknown status HIV Infections
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
DAPTA (D-ala-peptide T-amide) is a synthetic peptide that prevents HIV entry by blocking binding of HIV gp120 protein with CCR5 receptor. In a small clinical study of internasal formulation of DAPTA in long-term infected HIV patients, administration of DAPTA led to decrease in the amount of virus isolated from white blood cells, an increase in gamma-interferon secreting T-cells in the absense of drug-related toxicity. In another clinical study DAPTA in combination with antiretroviral therapy reduced the peripheral (plasma and serum) viral load, but did not reduce the CSF viral load.
Status:
Investigational
Source:
Psychopharmacol Bull. 1991;27(3):237-45.: Phase 2 Human clinical trial Completed Acquired Immunodeficiency Syndrome/psychology
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT03781947: Phase 1 Interventional Completed Healthy
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Teverelix is a polypeptide gonadotropin-releasing hormone (GnRH) antagonist which was being developed by Ardana Bioscience for the treatment of prostate cancer and benign prostatic hyperplasia. Compared with other GnRH antagonists, Teverelix is characterized by relatively good water solubility, little in vitro aggregation, and low histamine-releasing potency, with a dose that produces the halfmaximal response. In preclinical studies, Teverelix has been shown to exert antiovulatory activity. In phase I clinical trials Teverelix shows pronounced luteinizing hormone and testosterone suppressive effects after single subcutaneous doses in healthy men.
Status:
Investigational
Source:
NCT04105010: Phase 2 Interventional Completed Relapsed or Refractory Peripheral T Cell Lymphoma
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
INN:becondogrel [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02217800: Phase 2 Interventional Completed Acromegaly
(2013)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Somatoprim (DG3173) is a heptapeptide somatostatin analog (SSA) that binds with high affinity to sstr2, sstr4 and sstr5 and shows a very low insulin suppression in contrast to other SSA. Initially developed by Ipsen, it is under active development by licensee Aspireo Pharmaceuticals, an Israeli company.
In vitro as well as in vivo testing showed a dose-dependent GH lowering effect. Somatoprim has demonstrated a unique receptor binding and pharmacological profile which is differentiated from SSAs that are currently marketed or in clinical development. In particular, Somatoprim has shown an improved side effect profile with reduced adverse effects on the gastrointestinal tract and glucose metabolism. Furthermore, assessment of growth hormone secretion in cultured human somatotroph adenoma tissue treated with Somatoprim indicates that it has the potential to increase the response rate of acromegalic patients to SSA therapy. Somatoprim is currently in phase I/II of clinical development.
Status:
Investigational
Source:
INN:ruzotolimod [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT04386980: Phase 3 Interventional Withdrawn Osteoarthritis, Knee
(2021)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Resiniferatoxin (RTX or RTX-107) is a vanilloid derived from a cactus-like plant (Euphoria resiniferous) and has anti-inflammatory activity. This compound is an agonist of the transient receptor potential vanilloid 1 (TRPV1). Resiniferatoxin produces analgesia by desensitizing the TRPV1 receptor. Findings of several studies have suggested a potential therapeutic use of the anti-inflammatory effect of resiniferatoxin. Phase I and II clinical trials have been completed or are underway, evaluating the safety and efficacy of resiniferatoxin in pain-related disorders such as osteoarthritis and cancers.
Status:
Investigational
Source:
NCT00563433: Phase 3 Interventional Completed Diabetic Foot Ulcers
(1994)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Pexiganan is a 22-amino-acid synthetic cationic peptide. It is an analog of magainin 2, which is a host defense peptide isolated from frog skin. The drug is thought to act by disturbing the permeability of the cell membrane or cell wall. Pexiganan exhibited in vitro broad-spectrum antibacterial activity when it was tested against 3,109 clinical isolates of gram-positive and gram-negative, anaerobic and aerobic bacteria. It is currently in phase 3 clinical trials as a topical antimicrobial agent for the treatment of mild infections associated with diabetic foot ulcers. In vitro data for pexiganan acetate suggest that the drug does have hemolytic activity at concentrations relevant for antibacterial activity. In association with tigecycline, pexiganan administration could overcome antibiotic resistance and increase the effectiveness of treatment against P. aeruginosa sepsis.
